↓ Skip to main content

Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2

Overview of attention for article published in Breast Cancer Research, February 2016
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (93rd percentile)
  • High Attention Score compared to outputs of the same age and source (99th percentile)

Mentioned by

1 blog
33 tweeters
5 Facebook pages


72 Dimensions

Readers on

141 Mendeley
1 CiteULike
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2
Published in
Breast Cancer Research, February 2016
DOI 10.1186/s13058-016-0671-y
Pubmed ID

Valentina Silvestri, Daniel Barrowdale, Anna Marie Mulligan, Susan L. Neuhausen, Stephen Fox, Beth Y. Karlan, Gillian Mitchell, Paul James, Darcy L. Thull, Kristin K. Zorn, Natalie J. Carter, Katherine L. Nathanson, Susan M. Domchek, Timothy R. Rebbeck, Susan J. Ramus, Robert L. Nussbaum, Olufunmilayo I. Olopade, Johanna Rantala, Sook-Yee Yoon, Maria A. Caligo, Laura Spugnesi, Anders Bojesen, Inge Sokilde Pedersen, Mads Thomassen, Uffe Birk Jensen, Amanda Ewart Toland, Leigha Senter, Irene L. Andrulis, Gord Glendon, Peter J. Hulick, Evgeny N. Imyanitov, Mark H. Greene, Phuong L. Mai, Christian F. Singer, Christine Rappaport-Fuerhauser, Gero Kramer, Joseph Vijai, Kenneth Offit, Mark Robson, Anne Lincoln, Lauren Jacobs, Eva Machackova, Lenka Foretova, Marie Navratilova, Petra Vasickova, Fergus J. Couch, Emily Hallberg, Kathryn J. Ruddy, Priyanka Sharma, Sung-Won Kim, Manuel R. Teixeira, Pedro Pinto, Marco Montagna, Laura Matricardi, Adalgeir Arason, Oskar Th Johannsson, Rosa B. Barkardottir, Anna Jakubowska, Jan Lubinski, Angel Izquierdo, Miguel Angel Pujana, Judith Balmaña, Orland Diez, Gabriella Ivady, Janos Papp, Edith Olah, Ava Kwong, Heli Nevanlinna, Kristiina Aittomäki, Pedro Perez Segura, Trinidad Caldes, Tom Van Maerken, Bruce Poppe, Kathleen B. M. Claes, Claudine Isaacs, Camille Elan, Christine Lasset, Dominique Stoppa-Lyonnet, Laure Barjhoux, Muriel Belotti, Alfons Meindl, Andrea Gehrig, Christian Sutter, Christoph Engel, Dieter Niederacher, Doris Steinemann, Eric Hahnen, Karin Kast, Norbert Arnold, Raymonda Varon-Mateeva, Dorothea Wand, Andrew K. Godwin, D. Gareth Evans, Debra Frost, Jo Perkins, Julian Adlard, Louise Izatt, Radka Platte, Ros Eeles, Steve Ellis, Ute Hamann, Judy Garber, Florentia Fostira, George Fountzilas, Barbara Pasini, Giuseppe Giannini, Piera Rizzolo, Antonio Russo, Laura Cortesi, Laura Papi, Liliana Varesco, Domenico Palli, Ines Zanna, Antonella Savarese, Paolo Radice, Siranoush Manoukian, Bernard Peissel, Monica Barile, Bernardo Bonanni, Alessandra Viel, Valeria Pensotti, Stefania Tommasi, Paolo Peterlongo, Jeffrey N. Weitzel, Ana Osorio, Javier Benitez, Lesley McGuffog, Sue Healey, Anne-Marie Gerdes, Bent Ejlertsen, Thomas V. O. Hansen, Linda Steele, Yuan Chun Ding, Nadine Tung, Ramunas Janavicius, David E. Goldgar, Saundra S. Buys, Mary B. Daly, Anita Bane, Mary Beth Terry, Esther M. John, Melissa Southey, Douglas F. Easton, Georgia Chenevix-Trench, Antonis C. Antoniou, Laura Ottini


BRCA1 and, more commonly, BRCA2 mutations are associated with increased risk of male breast cancer (MBC). However, only a paucity of data exists on the pathology of breast cancers (BCs) in men with BRCA1/2 mutations. Using the largest available dataset, we determined whether MBCs arising in BRCA1/2 mutation carriers display specific pathologic features and whether these features differ from those of BRCA1/2 female BCs (FBCs). We characterised the pathologic features of 419 BRCA1/2 MBCs and, using logistic regression analysis, contrasted those with data from 9675 BRCA1/2 FBCs and with population-based data from 6351 MBCs in the Surveillance, Epidemiology, and End Results (SEER) database. Among BRCA2 MBCs, grade significantly decreased with increasing age at diagnosis (P = 0.005). Compared with BRCA2 FBCs, BRCA2 MBCs were of significantly higher stage (P for trend = 2 × 10(-5)) and higher grade (P for trend = 0.005) and were more likely to be oestrogen receptor-positive [odds ratio (OR) 10.59; 95 % confidence interval (CI) 5.15-21.80] and progesterone receptor-positive (OR 5.04; 95 % CI 3.17-8.04). With the exception of grade, similar patterns of associations emerged when we compared BRCA1 MBCs and FBCs. BRCA2 MBCs also presented with higher grade than MBCs from the SEER database (P for trend = 4 × 10(-12)). On the basis of the largest series analysed to date, our results show that BRCA1/2 MBCs display distinct pathologic characteristics compared with BRCA1/2 FBCs, and we identified a specific BRCA2-associated MBC phenotype characterised by a variable suggesting greater biological aggressiveness (i.e., high histologic grade). These findings could lead to the development of gender-specific risk prediction models and guide clinical strategies appropriate for MBC management.

Twitter Demographics

The data shown below were collected from the profiles of 33 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 141 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Finland 1 <1%
India 1 <1%
Slovakia 1 <1%
Unknown 138 98%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 17 12%
Student > Master 17 12%
Researcher 15 11%
Student > Postgraduate 12 9%
Student > Bachelor 10 7%
Other 33 23%
Unknown 37 26%
Readers by discipline Count As %
Medicine and Dentistry 45 32%
Biochemistry, Genetics and Molecular Biology 25 18%
Agricultural and Biological Sciences 14 10%
Nursing and Health Professions 5 4%
Computer Science 4 3%
Other 10 7%
Unknown 38 27%

Attention Score in Context

This research output has an Altmetric Attention Score of 28. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 20 August 2021.
All research outputs
of 21,839,802 outputs
Outputs from Breast Cancer Research
of 1,855 outputs
Outputs of similar age
of 378,733 outputs
Outputs of similar age from Breast Cancer Research
of 13 outputs
Altmetric has tracked 21,839,802 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 94th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,855 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 11.8. This one has done particularly well, scoring higher than 94% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 378,733 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 93% of its contemporaries.
We're also able to compare this research output to 13 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 99% of its contemporaries.